<DOC>
	<DOC>NCT01514500</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of NNC0195-0092 compared to placebo in healthy male subjects.</brief_summary>
	<brief_title>First Human Dose Trial of NNC0195-0092 in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism, Pituitary</mesh_term>
	<criteria>Healthy, nonsmoking male subjects BMI (body mass index) between 18.0 and 28.0 kg/m^2, both incl. Body weight 50 to 100 kg, both incl. Strenuous exercise within 4 days prior to dosing Receipt of any investigational medicinal product within 3 months prior to randomisation</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>